


## LIT-001

<b>Cat. No.:</b>	HY-124733A		
<b>CAS No.:</b>	2245072-21-1		
<b>Molecular Formula:</b>	C <sub>30</sub> H <sub>34</sub> F <sub>3</sub> N <sub>7</sub> O <sub>4</sub> S		
<b>Molecular Weight:</b>	645.7		
<b>Target:</b>	Oxytocin Receptor		
<b>Pathway:</b>	GPCR/G Protein		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 250 mg/mL (387.18 mM; Need ultrasonic)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.5487 mL	7.7435 mL	15.4871 mL
	5 mM		0.3097 mL	1.5487 mL	3.0974 mL
	10 mM		0.1549 mL	0.7744 mL	1.5487 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.17 mg/mL (3.36 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.17 mg/mL (3.36 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.17 mg/mL (3.36 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC<sub>50</sub>=55 nM; K<sub>i</sub>=226 nM). LIT-001 improves social interaction in a mouse model of autism<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

EC<sub>50</sub>: 55 nM (OT-R)<sup>[1]</sup>  
K<sub>i</sub>: 226 nM (OT-R)<sup>[1]</sup>

#### In Vitro

In vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with

minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

LIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD)<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Oprm1 <sup>-/-</sup> mice (bred in house on a 50% 129SVPas-50% C57BL/6J hybrid background) <sup>[1]</sup>
Dosage:	10, 20 mg/kg
Administration:	i.p.
Result:	Alleviated core symptoms in the context of ASD.

## REFERENCES

[1]. Frantz MC, et al. LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. J Med Chem. 2018 Oct 11;61(19):8670-8692.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA